Vacinação contra o papilomavírus humano e rastreamento de lesões anais

Autores

DOI:

https://doi.org/10.5327/2237-4574-238

Resumo

***

Referências

Karita HCS, Magaret AS, Doody DR, Schouten JT, Mao C, Huh WK, et al. Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): a randomized, double-blind, placebo-controlled trial. Int J Cancer. 2026;158(11):2983-94. https://doi.org/10.1002/ijc.70366

Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. https://doi.org/10.1093/cid/ciy274

Bennis SL, Yared NF, Horvath KJ, Baker JV, Waterboer T, Thyagarajan B, et al. HPV vaccination status in HIV-negative MSM and its association with high-risk HPV detection using HPV serology and anorectal swabs. Vaccines (Basel). 2024;12(10):1154. https://doi.org/10.3390/vaccines12101154

Albuquerque A, Fontes F. Recent guidelines on anal cancer screening: a systematic review. J Low Genit Tract Dis. 2025;29(2):180-5. https://doi.org/10.1097/lgt.0000000000000878

Downloads

Publicado

2026-08-11

Como Citar

1.
Guimarães ICC do V, Borba MR, de Carvalho NS, Alves RRF, Nadal SR, Manzione TS, et al. Vacinação contra o papilomavírus humano e rastreamento de lesões anais. Rev Bras Patol Trato Genit Inferior [Internet]. 11º de agosto de 2026 [citado 29º de agosto de 2026];10(01). Disponível em: https://rbptgi.emnuvens.com.br/revista/article/view/238

Edição

Seção

Recomendações Técnicas